Amarin Corp Plcuk (AMRN) Operating Income (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Operating Income of -$11.3 million for Q1 2026, up 32.35% YoY from -$8.6 million in Q1 2025, and down 132.54% sequentially from $34.8 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Operating Income (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Operating Income across 17 years of filings, most recently posting -$11.3 million for Q1 2026.
- In Q1 2026, Operating Income rose 32.35% year-over-year to -$11.3 million; the TTM figure through Mar 2026 stood at -$3.6 million (up 84.03% YoY), while the FY2025 annual figure was -$9.0 million, up 53.31% from the prior year.
- Operating Income slipped to -$11.3 million in Q1 2026, from $34.8 million in the prior quarter.
- Over the last five years, Operating Income for AMRN reached as high as $49.3 million in Q4 2023 and fell as low as -$62.8 million in Q2 2022.
- The 5-year median for Operating Income is -$13.6 million (2024), against an average of -$9.3 million.
- Annual changes were most pronounced in 2023 — Operating Income soared 614.64% — and 2025, when it sank 2950.57%.
- A 5-year view of Operating Income shows it stood at -$9.6 million in 2022, then soared by 614.64% to $49.3 million in 2023, then tumbled by 59.51% to $20.0 million in 2024, then jumped by 74.38% to $34.8 million in 2025, then plunged by 132.54% to -$11.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$11.3 million, $34.8 million, and -$11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 9.50 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 6.36 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.99 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 4.25 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -11.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.33 Mn |
| Dec 31, 2025 | 34.83 Mn |
| Sep 30, 2025 | -11.10 Mn |
| Jun 30, 2025 | -15.99 Mn |
| Mar 31, 2025 | -16.76 Mn |
| Dec 31, 2024 | 19.98 Mn |
| Sep 30, 2024 | -25.17 Mn |
| Jun 30, 2024 | -524,000.00 |
| Mar 31, 2024 | -13.58 Mn |
| Dec 31, 2023 | 49.33 Mn |
| Sep 30, 2023 | -21.45 Mn |
| Jun 30, 2023 | -23.96 Mn |
| Mar 31, 2023 | -17.34 Mn |
| Dec 31, 2022 | -9.59 Mn |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -62.83 Mn |
| Mar 31, 2022 | -28.31 Mn |
| Dec 31, 2021 | 8.45 Mn |
| Sep 30, 2021 | -13.07 Mn |
| Jun 30, 2021 | 8.77 Mn |